Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-11-03
Based on 493 first isolates · MED-A · Febrile UTI / pyelonephritis · 2023-11-05 → 2024-11-03
Internal medicine A
Per-organism detail: MED-A urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ciprofloxacin 81 % (77 %–84 %)
Not covered: Enterococcus faecalis (9 %), Escherichia coli (4 %), Staphylococcus aureus (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
85 %
n = 46
nitrofurantoin NIT
trend · Escherichia coli not for this site
82 %
76 %
n = 46
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
80 %
n = 46
ciprofloxacin CIP
trend · Escherichia coli
81 %
83 %
n = 46
ceftriaxone CRO
trend · Escherichia coli
78 %
70 %
n = 46
mecillinam MEC
trend · Escherichia coli not for this site
77 %
70 %
n = 46
72 %
59 %
n = 46
trimethoprim TMP
trend · Escherichia coli not for this site
72 %
54 %
n = 46
47 %
52 %
n = 46
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
15 %
n = 46
5 %
13 %
n = 46
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
2 %
n = 46

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
10 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
6 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.